Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Xenon Pharmaceuticals Inc
XENE | US
55.24
USD-0.17
-0.31%
XENE | US
Loading StockChartView...
About Xenon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
55.24
Open
55.42
High
55.56
Low
54.31
Xenon Pharmaceuticals Inc. a clinical-stage biopharmaceutical company engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496 a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101 a Kv7 potassium channel opener which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352 a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy and other indications including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby Canada.
View LessXENE | US
Risk
33.0
Sharpe
0.67
Luna's Score
42/100
Recommendation
Sell
Luna says (XENE | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
27.7%1 month
33.0%3 months
103.8%6 months
77.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.89
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-11.81
Ent. to rev.
10.87K
PEG
-0.06
Other Fundamentals
EBITDA
-233.68M
MarketCap
4.19B
MarketCap(USD)
4.19B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-26.71
Short ratio
10.62
Short perc.
4.39
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
5.67
Range1M
6.37
Range3M
23.66
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.58
Price X volume
29.43M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.81 | 0.53 | Cheaper |
| Ent. to Revenue | 10,874.60 | 3,967.00 | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.89 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 103.79 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 4.19B | 3.66B | Par |
